We selected PD-L1 as the target to further understand the impact of PARP-2 on HCC development, because the above results suggested that inactivation of PARP-2 expression might lead to the elevation of PD-L1 in HCC patients. The gene discussed is PARP2; the disease is hepatocellular carcinoma.